Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Ruben A. Mesa, MD, Ronald Hoffman, MD, Heidi E. Kosiorek, MS, Josef T. Prchal, MD, Claire N. Harrison, DM, FRCP, FRCPath, Mary Frances McMullin, MD, Abdulraheem Yacoub, MD, Alessandro Rambaldi, MD, Dmitriy Berenzon, MD, Alessandro M. Vannucchi, MD PhD, Joanne C Ewing, PhD BMBS, BSc, FRPATH,, Casey L O'Connell, MD, Jean-Jacques Kiladjian, MD PhD, Adam Mead, MD PhD, Elliott F. Winton, MD, David S. Leibowitz, MD, Valerio De Stefano, MD, Murat O. Arcasoy, MD, Craig M. Kessler, MD, Rosalind Catchatorian, Damiano Rondelli, MD, Richard T. Silver, MD, Ellen K. Ritchie, MD, Arnon Nagler, Marina Kremyanskaya, MD PhD, Richard F. Schlenk, MD, Rona Singer Weinberg, PhD, Mohamed E Salama, MD, Gianni Tognoni, Giuseppe Prosperini, Alessandra Di Lelio, Eliseo Serone, Lorenzo Marfisi, Alicia Orellana, MD, Tiziano Barbui, MD, Amylou C. Dueck, PhD, John O. Mascarenhas, MD MS

Blood (2016) 128 (22): 4271.

https://doi.org/10.1182/blood.V128.22.4271.4271

Published: 2016

Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)

Blood (2016) 128 (22): 1124.

https://doi.org/10.1182/blood.V128.22.1124.1124

Published: 2016

Journal Articles

Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC)

Blood (2016) 128 (22): 1126.

https://doi.org/10.1182/blood.V128.22.1126.1126

Published: 2016

Journal Articles

Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia

John O. Mascarenhas, MD MS, Josef T. Prchal, MD, Alessandro Rambaldi, MD, Ruben A. Mesa, MD, Dmitriy Berenzon, MD, Abdulraheem Yacoub, MD, Claire N. Harrison, DM, FRCP, FRCPath, Mary Frances McMullin, MD, Alessandro M. Vannucchi, MD PhD, Joanne C Ewing, PhD BMBS, BSc, FRPATH,, Casey L O'Connell, MD, Jean-Jacques Kiladjian, MD PhD, Adam Mead, MD PhD, Elliott F. Winton, MD, David S. Leibowitz, MD, Valerio De Stefano, Murat O. Arcasoy, MD, Craig M. Kessler, MD, Rosalind Catchatorian, Damiano Rondelli, MD, Richard T. Silver, MD, Ellen K. Ritchie, MD, Arnon Nagler, Marina Kremyanskaya, MD PhD, Richard F. Schlenk, MD, Rona Singer Weinberg, PhD, Mohamed E Salama, MD, Gianni Tognoni, Giuseppe Prosperini, Alessandra Di Lelio, Eliseo Serone, Lorenzo Marfisi, Jill Kleczko, Heidi E. Kosiorek, MS, Tiziano Barbui, MD, Amylou C. Dueck, PhD, Ronald Hoffman, MD

Blood (2016) 128 (22): 479.

https://doi.org/10.1182/blood.V128.22.479.479

Published: 2016

Journal Articles

PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks

Srdan Verstovsek, MD, Ruben A. Mesa, Lynda M Foltz, MD, Vikas Gupta, MD MRCP, MRCPath, John O. Mascarenhas, MD MS, Ellen K. Ritchie, MD, Ronald Hoffman, MD, Richard T. Silver, MD, Marina Kremyanskaya, MDPhD, Olga Pozdnyakova, MD, Robert P. Hasserjian, MD, Elizabeth Trehu, MD, Mohamed E Salama, MD, Hagop M Kantarjian, MD, Jason Gotlib, MD

Blood (2015) 126 (23): 56.

https://doi.org/10.1182/blood.V126.23.56.56

Published: 2015

Journal Articles

Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States

Shreekant V. Parasuraman, PhD, Ahmad B. Naim, MD, Dilan C. Paranagama, PhD, Maureen Thyne, PA, Sara Goldberger, LCSW-R, John O. Mascarenhas, MD MS, James Mangan, MD PhD, Salman Fazal, MD, Carole B. Miller, MD, Ruben A. Mesa

Blood (2015) 126 (23): 5561.

https://doi.org/10.1182/blood.V126.23.5561.5561

Published: 2015

Journal Articles

Phlebotomy Frequency and Quality of Life and Productivity in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States

Salman Fazal, MD, Carole B. Miller, MD, John O. Mascarenhas, MD MS, Maureen Thyne, PA, Sara Goldberger, LCSW-R, Dilan C. Paranagama, PhD, Shreekant V. Parasuraman, PhD, Ahmad B. Naim, MD, James Mangan, MD PhD, Ruben A. Mesa

Blood (2015) 126 (23): 5184.

https://doi.org/10.1182/blood.V126.23.5184.5184

Published: 2015

Journal Articles

An Inhibitor of TGF-β Promotes Proliferation of Normal but Not MPN Hematopoietic Cells and Is a Candidate Therapeutic Agent for the Treatment of MPN Patients Carrying JAK2 V617F or Calr pQ365fs Mutations

Anna Rita Migliaccio, PhD, Camelia Iancu-Rubin, PhD, Rona Singer Weinberg, PhD, Ronald Hoffman, MD, Amylou Constance Dueck, PhD, John O. Mascarenhas, MD MS

Blood (2015) 126 (23): 4089.

https://doi.org/10.1182/blood.V126.23.4089.4089

Published: 2015

Journal Articles

Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States

Ruben A. Mesa, Carole B. Miller, MD, John O. Mascarenhas, MD MS, Maureen Thyne, PA, Sara Goldberger, LCSW-R, Dilan C. Paranagama, PhD, Shreekant V. Parasuraman, PhD, Salman Fazal, MD, Ahmad B. Naim, MD, James Mangan, MD PhD

Blood (2015) 126 (23): 4077.

https://doi.org/10.1182/blood.V126.23.4077.4077

Published: 2015

Journal Articles

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results

Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD, Lynda M Foltz, MD, Vikas Gupta, MD FRCP, FRCPath, John O Mascarenhas, MD MS, Ellen K. Ritchie, MD, Ronald Hoffman, MD, Richard T. Silver, MD, Marina Kremyanskaya, MDPhD, Olga Pozdnyakova, MD PhD, Robert P Hasserjian, MD, Elizabeth Trehu, MD, Hagop M. Kantarjian, MD, Jason R. Gotlib, MD

Blood (2014) 124 (21): 713.

https://doi.org/10.1182/blood.V124.21.713.713

Published: 2014

Journal Articles

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

John O Mascarenhas, MD MS, Moshe Talpaz, Vikas Gupta, MD FRCP, FRCPath, Lynda M Foltz, MD FRCP, Michael R Savona, MD, Ron Paquette, MD, Robert Turner, MD, Paul Coughlin, PhD MBBS, Elliott Winton, MD, Deborah Hunter, PhD, Albert Assad, MD, Jason Clark, PhD, Peter O'Neill, MBA, CCRP, Ronald Hoffman, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 714.

https://doi.org/10.1182/blood.V124.21.714.714

Published: 2014

Journal Articles

Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY

Ruben Mesa, MD, Carole B Miller, MD, Maureen Thyne, PA, James Mangan, MD PhD, Sara Goldberger, LCSW-R, Salman Fazal, MD, Xiaomei Ma, PhD, Wendy Wilson, RN, MSN, OCN, David G Dubinski, MBA, John Boyle, PhD, John O Mascarenhas, MD MS

Blood (2014) 124 (21): 4827.

https://doi.org/10.1182/blood.V124.21.4827.4827

Published: 2014

Journal Articles

Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia

Krisstina L. Gowin, DO, Amylou C. Dueck, PhD, John O Mascarenhas, MD MS, Ronald Hoffman, MD, Craig B. Reeder, MD, John Camoriano, MD, Katherine Gano, MS, Vineta Ghurye, Sravan Nagi Reddy, Patricia Koenig, Veena Fauble, MD, Raoul Tibes, MD, Ruben Mesa, MD

Blood (2014) 124 (21): 3206.

https://doi.org/10.1182/blood.V124.21.3206.3206

Published: 2014

Journal Articles

Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States

Blood (2014) 124 (21): 3183.

https://doi.org/10.1182/blood.V124.21.3183.3183

Published: 2014

Journal Articles

Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression

Vesna Najfeld, PhD, Joseph Tripodi, MS, Xiaoli Wang, MD PhD, Myron Schwartz, MD, Marina Kremyanskaya, MDPhD, Edward Cytryn, Sharon Zirkiev, Raajit K. Rampal, MD, PhD, John O Mascarenhas, MD MS, Ronald Hoffman, MD

Blood (2014) 124 (21): 1871.

https://doi.org/10.1182/blood.V124.21.1871.1871

Published: 2014

NARROW

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)

Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC)

Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia

PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks

Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States

Phlebotomy Frequency and Quality of Life and Productivity in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States

An Inhibitor of TGF-β Promotes Proliferation of Normal but Not MPN Hematopoietic Cells and Is a Candidate Therapeutic Agent for the Treatment of MPN Patients Carrying JAK2 V617F or Calr pQ365fs Mutations

Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY

Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia

Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States

Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only